Is COVID Causing Pancreatic Cancer: Key Insights

No reliable evidence shows that COVID-19 directly causes pancreatic cancer. The concern has circulated widely since the pandemic, fueled by reports of the virus infecting pancreatic cells and by bioinformatics studies identifying shared molecular pathways between SARS-CoV-2 infection and pancreatic tumors. But population-level cancer data collected during and after the pandemic tell a different story: pancreatic cancer diagnoses did not spike in the wake of COVID-19 waves. The relationship between the two diseases is real at the cellular and immunological level, but the jump from “the virus affects the pancreas” to “the virus causes pancreatic cancer” is enormous, and the data so far do not support it.

What the Epidemiological Numbers Actually Show

If COVID-19 were triggering pancreatic cancer at meaningful rates, you would expect to see an uptick in new cases starting in 2020 or 2021, as hundreds of millions of people were infected worldwide. The opposite happened. A large U.S. analysis using the Surveillance, Epidemiology, and End Results (SEER) database found that the number of pancreatic ductal adenocarcinoma cases diagnosed nationally dropped from 13,457 in 2019 to 13,153 in 2020, then rose to 13,998 in 2021.¹ A separate study using a broader dataset of over 127,000 U.S. patients found that pancreatic cancer diagnoses had been rising steadily from 2017 to 2019 but dipped in 2020.²

That 2020 dip, followed by a rebound, is the signature of disrupted healthcare access, not a new cause of cancer. Hospitals postponed elective imaging, patients delayed visits, and screening programs paused. The 2021 bounce reflects catch-up diagnoses as the healthcare system reopened. A Turkish cohort study comparing annual pancreatic cancer incidence rates before and during the pandemic found them nearly identical: about 137 cases per year in the pre-COVID period versus roughly 135 during COVID.³ None of these datasets show the kind of incidence surge you would need to connect SARS-CoV-2 infection to new pancreatic cancers at a population level.

How the Virus Reaches the Pancreas

SARS-CoV-2 enters cells primarily through a surface protein called ACE2, which is present in the lungs, gut, heart, and, to a debated degree, the pancreas. Some studies have detected ACE2 on insulin-producing beta cells, while others have found little or no expression there. This contradictory evidence means researchers are still debating whether the virus routinely infects pancreatic cells in living patients or whether laboratory conditions exaggerate the interaction.⁴

Lab experiments have shown that SARS-CoV-2 can enter pancreatic cells under controlled conditions. One study using human stem-cell-derived pancreatic organoids and mouse models demonstrated that a pseudovirus engineered to mimic SARS-CoV-2 entry infected both beta cells (which make insulin) and alpha cells (which make glucagon). Viral markers were detected in implanted pancreatic tissue in mice that had been inoculated with the virus, but not in mock-infected controls.⁵ This confirms that the virus can get in, but infecting a cell in a dish is very different from causing cancer in a person. The overwhelming majority of viruses that infect an organ do not lead to malignancy there.

Shared Molecular Pathways and Why They Are Overinterpreted

A handful of bioinformatics studies have compared gene-expression data from COVID-19 patients with gene-expression data from pancreatic cancer patients and found overlapping genes. One analysis identified 236 genes that were differentially expressed in both conditions, with functional analysis suggesting involvement in pathways related to viral replication and tumor development.⁶ Another review noted that key genes involved in tumor suppression and cell-death regulation, such as PTEN, CASP3, and SMAD3, may be upregulated in pancreatic tissue in response to the virus, and that chronic inflammation from the immune response could theoretically facilitate cancer development.⁷

These findings sound alarming, but they need context. The human genome has roughly 20,000 protein-coding genes. Any two diseases that involve inflammation, cell stress, or immune activation will share hundreds of differentially expressed genes simply because those are the body’s general-purpose alarm responses. Finding overlap between COVID-19 and pancreatic cancer gene expression does not mean one causes the other any more than finding that both a house fire and a forest fire involve oxygen means one causes the other. Shared pathways are a starting point for investigation, not evidence of causation. The studies themselves frame their results as hypothesis-generating, but the framing often gets lost when the findings travel through social media and health news.

How Pandemic Disruptions Affected Pancreatic Cancer Patients

While COVID-19 probably did not cause new pancreatic cancers, the pandemic genuinely harmed people who already had the disease or were developing it. Pancreatic cancer is notoriously hard to catch early. It rarely causes symptoms in its initial stages, and when it does, the symptoms, such as back pain, weight loss, and digestive changes, are vague enough to be attributed to other causes. Early detection often depends on incidental findings during imaging done for other reasons.

A study examining CT scans performed before a pancreatic cancer diagnosis found that over half of patients had findings suggestive of pancreatic cancer on earlier scans, including mass-like lesions, focal dilation of the pancreatic duct, and distal tissue atrophy.⁸ This means opportunities for earlier detection existed but were missed even under normal circumstances. During the pandemic, with imaging appointments postponed and emergency departments overwhelmed by COVID patients, those opportunities shrank further. The 2020 dip in diagnoses seen in the SEER and national datasets almost certainly reflects cancers that went undetected for longer, not cancers that stopped forming.

Late detection matters enormously for pancreatic cancer. It is one of the few cancers where stage at diagnosis largely determines whether surgery is even an option, and surgery is the only treatment that offers any realistic chance of long-term survival. Patients diagnosed during the pandemic were more likely to present at advanced stages, and treatment timelines were often stretched by hospital capacity constraints.² This is the most concrete and well-documented harm the pandemic inflicted on pancreatic cancer patients, and it is a healthcare-system problem, not a viral one.

When a Tumor Marker Spikes After COVID Vaccination

Some people have had blood tests show dramatically elevated levels of CA 19-9, a marker commonly used to monitor pancreatic cancer, shortly after receiving a COVID-19 vaccine. In one documented case, the marker exceeded 12,000 U/mL, more than 300 times the normal upper limit. Imaging showed no malignancy; instead, changes consistent with autoimmune pancreatitis were identified. The elevated marker level was ultimately attributed to a benign inflammatory reaction rather than cancer.⁹

CA 19-9 is a frustratingly imprecise marker. It can be elevated in pancreatitis, liver disease, bile duct obstruction, and other inflammatory conditions that have nothing to do with cancer. A spike after vaccination is an example of the immune system’s inflammatory response temporarily pushing the marker up. If you are someone who had a high CA 19-9 reading around the time of a COVID vaccination, the reading alone does not indicate cancer, but it does warrant follow-up imaging. The practical lesson is that CA 19-9 values need to be interpreted alongside imaging findings, not in isolation, and that clinicians should ask about recent vaccination when an unexplained spike appears.

The New-Onset Diabetes Connection

One plausible indirect pathway between COVID-19 and pancreatic cancer risk runs through diabetes. COVID-19 has been linked to new cases of both type 1 and type 2 diabetes developing after infection, with risk highest among those who were hospitalized or had severe illness. A systematic review recommended that healthcare providers monitor COVID-19 survivors for signs of new-onset diabetes, with regular screening especially during the first year after infection for people with pre-existing metabolic risk factors.¹⁰

Long-standing type 2 diabetes is an established risk factor for pancreatic cancer. It raises the baseline risk modestly, and the relationship appears to go both ways: pancreatic tumors themselves can cause diabetes by disrupting insulin production, a phenomenon sometimes called “type 3c” diabetes. So if COVID-19 leads to new cases of diabetes, and diabetes is a risk factor for pancreatic cancer, could the virus indirectly raise pancreatic cancer risk over the long term? In theory, yes, but the absolute magnitude would be tiny. Diabetes increases pancreatic cancer risk by roughly twofold over many years, and only a small fraction of people with diabetes develop pancreatic cancer. Even if COVID-19 produced a wave of new diabetes cases, the downstream effect on pancreatic cancer rates would take years to appear and would be difficult to distinguish from the background rise in pancreatic cancer that was already underway before the pandemic.

The more immediately useful takeaway is clinical. New-onset diabetes in an adult, particularly someone who develops it rapidly and without the usual risk factors like obesity, sometimes turns out to be an early sign of a pancreatic tumor that is already growing. Clinicians have long known that unexplained new diabetes in middle-aged and older adults deserves additional investigation, including pancreatic imaging. The pandemic-era increase in new diabetes diagnoses makes this screening question more relevant, not because COVID is causing cancer, but because any increase in diabetes raises the number of people for whom that clinical question needs to be asked.

Why Known Oncogenic Viruses Work Differently

The handful of viruses that genuinely cause cancer, such as human papillomavirus (HPV) with cervical cancer and hepatitis B and C with liver cancer, do so through specific, well-characterized mechanisms. They typically integrate their genetic material into the host cell’s DNA, directly disable tumor-suppressor genes, or create a state of chronic infection lasting years or decades that gradually accumulates DNA damage. SARS-CoV-2 does not behave this way. It is an RNA virus that replicates in the cell’s cytoplasm and does not integrate into the host genome. Its infections are generally acute, lasting days to weeks, not the chronic years-long infections characteristic of oncogenic viruses.

The review noting potential viral oncogenesis from SARS-CoV-2 frames the concern in terms of gene-expression changes and chronic inflammation rather than the classic mechanisms of viral carcinogenesis.⁷ Those are legitimate biological effects, but inflammation-driven oncogenesis typically requires sustained exposure over long periods. A two-week respiratory infection, even a severe one, produces a very different inflammatory timeline than decades of chronic hepatitis. This does not rule out the possibility entirely, but it places COVID-19 in a fundamentally different category from the viruses we know cause cancer.

The Immune Exhaustion Question

Pancreatic cancer is famously good at evading the immune system. The tumor microenvironment in pancreatic ductal adenocarcinoma is deeply immunosuppressive, filled with exhausted T cells that have lost their ability to kill cancer cells effectively. Research using single-cell sequencing has mapped the extent of this dysfunction, showing thousands of genes altered in exhausted CD8+ and CD4+ T cells within pancreatic tumors, a landscape of immune suppression that helps the cancer avoid destruction.¹¹

COVID-19 is known to temporarily alter immune cell populations, sometimes driving T-cell exhaustion during severe or prolonged infection. Could COVID-19-related immune exhaustion provide a window during which a pre-existing pancreatic lesion gains a growth advantage? The idea has biological plausibility but no direct evidence. The immune changes from acute COVID-19 tend to resolve over weeks to months in most people. For someone already harboring a precancerous pancreatic lesion, any transient period of weakened immune surveillance is a concern worth investigating, but it is speculative at this stage. No study has tracked a cohort of COVID-19 survivors and shown accelerated progression of precancerous pancreatic changes compared with uninfected controls.

KRAS Mutations and Pancreatic Cancer’s Own Biology

The vast majority of pancreatic ductal adenocarcinomas are driven by mutations in the KRAS gene, present in roughly 90 percent of cases. These mutations are acquired over time through processes like DNA replication errors, exposure to metabolic byproducts, and chronic inflammation of the pancreas from causes such as smoking, alcohol use, and pancreatitis. Research into KRAS-mutant pancreatic cancer cells has shown that these mutations also influence how tumors respond to chemotherapy, with KRAS-mutated cells showing higher rates of therapy-induced senescence, a state where cells stop dividing but resist death, potentially enabling recurrence.¹²

Understanding pancreatic cancer’s native biology matters here because it highlights how much of the disease’s progression is governed by internal mutational processes rather than external infections. A virus that transiently infects some pancreatic cells is working against a backdrop in which the dominant oncogenic event, a KRAS mutation, arises from the pancreas’s own cellular machinery over years. Even if SARS-CoV-2 contributed some degree of inflammation or cellular stress, it would be entering a causal chain already dominated by much more powerful drivers. This is not an argument that COVID-19 has zero effect on the pancreas, but rather that its potential contribution to pancreatic cancer risk would be marginal compared to the known risk factors like smoking, chronic pancreatitis, obesity, family history, and aging itself.

What Matters Practically

If you have had COVID-19 and are worried about pancreatic cancer, the most useful thing to know is that the current evidence does not support a direct causal link. The pandemic did, however, cause real diagnostic delays that may have moved some patients from an operable stage to an inoperable one, and that harm is worth acknowledging separately from the viral biology question. If you developed new-onset diabetes after a COVID-19 infection, particularly if you had no prior metabolic risk factors, mention it to your doctor. Not because COVID gave you cancer, but because new-onset diabetes in adults sometimes warrants pancreatic imaging regardless of its cause.¹⁰

If a blood test has shown an elevated CA 19-9 level around the time of a COVID-19 infection or vaccination, do not panic, but do follow up with imaging. The marker rises in many inflammatory conditions and is not specific to cancer. And if you are reading headlines about shared gene pathways between COVID and pancreatic cancer, remember that shared gene expression between two diseases is a common finding in bioinformatics research and does not establish that one disease causes the other. The science here is preliminary, hypothesis-generating, and a long way from clinical relevance. Pancreatic cancer research deserves more funding and attention on its own terms; it does not need the borrowed urgency of COVID-19 to justify it.